Andrew Siderowf, MD MS is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD at Duke University, residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester (under Ira Shoulson, MD. His research encompasses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures. He worked for 5 years at Avid Radiopharmaceuticals developing PET tracers for neurodegenerative disorders. Currently, Dr. Siderowf has leadership roles in multi-center clinical studies related to Parkinson’s disease. He is the Co-PI of the Parkinson Progression Marker Initiative (PPMI) and lead investigator for the Parkinson Study Group (PSG) in the SPARK study of passive anti-alpha synuclein immunotherapy for Parkinson’s disease (sponsored by Biogen). He also serves on the safety monitoring boards of several ongoing multi-center clinical trials.
Within the NeuroNEXT network, he is a co-PI at the University of Pennsylvania/CHOP clinical site in Philadelphia, PA.